breast cancer

From Aaushi
Jump to navigation Jump to search

Classification

Etiology

Epidemiology

  • 10-12% of women will develop breast cancer
  • incidence is highest non-hispanic whites, 2nd in black women[4]
  • incidence of breast cancer increases with age
    • 95% of cases occur in women > 40 years of age
  • most common cause of cancer-related death in women age 35-54; 50% of breast cancer-related death occur in women < 50 years of age[78]
  • 3.5% will die of the disease
  • mortality rates are 15% higher in blacks despite a lower incidence of breast cancer[65]
  • incidence of metastatic breast cancer among women 25-39 years of age increased from 1.53/100,000 in 1976 to 2.90/100,000 in 2009[66]; higher among blacks, non-Hispanic whites, & those with estrogen receptor-positive tumors[66]

Pathology

Genetics

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

staging/prognosis

treatment modalities

locally advanced (T4) & inflammatory breast cancer

suspected recurrent breast cancer or metastases

established metastatic breast cancer & relapse

prognosis, fertility, follow-up, prevention

* osteoporosis therapy in estrogen-deprived patient

* bisphosphates lower breast cancer recurrence & mortality in postmenopausal women[102]

* 3-5 years of bisphosphonate treatment (current recommendations)

Notes

More general terms

More specific terms

Additional terms

References

  1. 1.0 1.1 Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 29, 408-410
  2. Northern California Kaiser Permanente Videoconference, Nov. 11, 1999
  3. 3.0 3.1 Journal Watch, Mass Med Soc 19(23):184 (Dec) 1999
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 4.31 4.32 4.33 4.34 4.35 4.36 4.37 4.38 4.39 4.40 4.41 4.42 4.43 4.44 4.45 4.46 4.47 4.48 4.49 4.50 4.51 4.52 4.53 4.54 4.55 4.56 4.57 4.58 4.59 4.60 4.61 4.62 4.63 4.64 4.65 4.66 4.67 4.68 4.69 4.70 4.71 4.72 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  5. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 665-670
  6. 6.0 6.1 The Prescriber's Letter, vol 7 #10, Oct 2000, pg 57
  7. 7.0 7.1 Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 521, 562-68
  8. 8.0 8.1 Genova, A, UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  9. Journal Watch 21(23):187, 2001 Schernhammer ES et al Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93:1563, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11604480
    Davis S et al Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11604479
  10. 10.0 10.1 The Prescriber's Letter, vol 9 #2, Feb 2002, pg 10
  11. Journal Watch 22(2):12, 2002
  12. 12.0 12.1 Journal Watch 22(3):22, 2002 Goodwin et al The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345:1719, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11742045
    Spiegel D. Mind matters - group therapy and survival in breast cancer. N Engl J Med 345:1767, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11742052
  13. 13.0 13.1 Journal Watch 22(5):40, 2002 van't Veer LJ et al Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11823860
  14. 14.0 14.1 14.2 14.3 Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004;
    Geriatric Review Syllabus, 7th edition Parada JT et al (eds) American Geriatrics Society, 2010
    Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
    Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016
  15. 15.0 15.1 Journal Watch 22(24):184, 2002 Fisher B et al Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12377957
    Whelan T A trial of two questions. J Clin Oncol 20:4135, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12377955
  16. 16.0 16.1 Journal Watch 23(4):32, 2003 Jonat W et al Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12488406
    Jakesz R et al Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12488405
    Pritchard KI Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift? J Clin Oncol 20:4611, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12488402
  17. Journal Watch 24(1):7, 2004
  18. Prescriber's Letter 11(3):16 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200315&pb=PRL (subscription needed) http://www.prescribersletter.com
  19. 19.0 19.1 Prescriber's Letter 11(4):22 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200408&pb=PRL (subscription needed) http://www.prescribersletter.com
  20. 20.0 20.1 Journal Watch 24(16):130, 2004 Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Reproductive history and mortality after breast cancer diagnosis. Obstet Gynecol. 2004 Jul;104(1):146-54. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15229014
  21. Breast Cancer (PDQ): Screening http://www.cancer.gov/cancertopics/pdq/screening/breast/HealthProfessional
  22. Breast Cancer (PDQ): Prevention http://www.cancer.gov/cancertopics/pdq/prevention/breast/HealthProfessional
  23. Genetics of Breast and Ovarian Cancer (PDQ) http://www.nci.nih.gov/cancerinfo/pdq/genetics/breast-and-ovarian
  24. Journal Watch 24(17):133, 2004 Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG; Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004 Jul 29;351(5):427-37. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15282350
  25. 25.0 25.1 Journal Watch 24(20):152-53, 2004 Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4;364(9437):858-68. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15351193
  26. Journal Watch 24(20):153, 2004
    Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 2;351(10):963-70. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15342804
    Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L; Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 2;351(10):971-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15342805
  27. 27.0 27.1 27.2 Journal Watch 24(21):164, 2004 Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004 Sep 15;292(11):1317-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15367553
  28. 28.0 28.1 Prescriber's Letter 12(1): 2005 Arimidex (Anastrozole) for Early Breast Cancer; an Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210113&pb=PRL (subscription needed) http://www.prescribersletter.com
  29. Journal Watch 25(8):67, 2005 Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, Tange UB, Blichert-Toft M, Rank F, Mouridsen H, Lynge E. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ. 2005 Jan 29;330(7485):220. Epub 2005 Jan 13. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15649904 <Internet> http://bmj.bmjjournals.com/cgi/content/full/330/7485/220
  30. 30.0 30.1 Journal Watch 25(12):94, 2005 Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 May 25;293(20):2479-86. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15914748
  31. 31.0 31.1 Journal Watch 25(14):112, 2005 Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM; MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005 May;365(9473):1769-78. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15910949 Warner E, Causer PA. MRI surveillance for hereditary breast-cancer risk. Lancet. 2005 May;365(9473):1747-9. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15910935
  32. 32.0 32.1 U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann Intern Med 2005 Sep 6; 143:355-61. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16144894 Corresponding NGC guideline withdrawn Jan 2011, revised May 2014
    Nelson HD et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005 Sep 6; 143:362-79. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16144895 Corresponding NGC guideline withdrawn Jan 2011, revised May 2014
    U.S. Preventive Services Task Force (USPSTF). Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Feb 18;160(4):271-81 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24366376
  33. 33.0 33.1 Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005 Aug 25;353(8):793-802. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16120859
  34. 34.0 34.1 Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005 Oct 12;294(14):1765-72. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16219879
  35. 35.0 35.1 The Breast Cancer International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16382061
  36. 36.0 36.1 Guarneri V et al, Long-term cardiac tolerability of trastuzumab in metastatic breast cancer. The M.D. Andersion Cancer Center experience. J Clin Oncol 2006, 24:4107 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16908934
    Harris EE et al, Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006, 24:4100 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16908933
  37. 37.0 37.1 37.2 Khatcheressian JL et al, American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006, 24:5091 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17033037
  38. 38.0 38.1 Oh JL et al, Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol 2006, 24:4971 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17075114
  39. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/17159189 <Internet> http://www.jco.org/cgi/content/full/25/1/118 Corresponding NGC guideline withdrawn Dec 2012
  40. The Role of Gemcitabine in the Management of Metastatic Breast Cancer: A Clinical Practice Guideline Dent S et al, Program in Evidence-based Care (PEBC) http://www.cancercare.on.ca/pdf/pebc1-12s.pdf
  41. 41.0 41.1 The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group Effect and anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18083636
  42. Muss HB et al Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup Trial MA.17. J Clin Oncol 2008 Apr 20; 26:1956. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18332474
    Mamounas EP et al Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol 2008 Apr 20; 26:1965. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18332472
    Goss PE et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008 Apr 20; 26:1948. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18332475
  43. 43.0 43.1 43.2 Zahl PH et al The Natural History of Invasive Breast Cancers Detected by Screening Mammography Arch Intern Med. 2008;168(21):2311-2316. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19029493
    Kaplan RM and Porzsolt F. The natural history of breast cancer. Arch Intern Med 2008 Nov 24; 168:2302. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19029491
  44. 44.0 44.1 Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27; 357:2666. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18160686
    FDA advisory committee does not recommend approval for Avastin for breast cancer. http://ecancertrials.com/Default.aspx?DocumentID=40958
    FDA MedWatch Avastin (bevacizumab): Process for Removal of Breast Cancer Indication Begun http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm
    Miller R. The biotech bottleneck. Wall Street Journal Dec 28 , 2007:A13 http://online.wsj.com/article/SB119880414063654409.html
  45. 45.0 45.1 45.2 Simmons C et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009 Mar 18; [e-pub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/19299408 <Internet> http://dx.doi.org/10.1093/annonc/mdp028
    Broom RJ Changes in estrogen receptor, progesterone receptor and her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res. 2009 May;29(5):1557-62. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19443366
  46. 46.0 46.1 46.2 Dawood S et al Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009 Apr; 20:621. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19150943
  47. 47.0 47.1 Morrow M et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 2009 Oct 14; 302:1551. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19826024
  48. 48.0 48.1 48.2 Gartner R et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 2009 Nov 11; 302:1985. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19903919
    Loftus LS and Laronga C. Evaluating patients with chronic pain after breast cancer surgery: The search for relief. JAMA 2009 Nov 11; 302:2034 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19903928
  49. 49.0 49.1 Holmes MD et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010 Feb 16; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20159825 <Internet> http://dx.doi.org/10.1200/JCO.2009.22.7918
  50. 50.0 50.1 Punglia RS et al Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: Retrospective cohort analysis. BMJ 2010 Mar 2; 340:c845 http://dx.doi.org/10.1136/bmj.c845 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20197326
  51. 51.0 51.1 Botteri E et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 2010 Apr; 21:723. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19833817
  52. 52.0 52.1 Burstein HJ et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010 Jul 12 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20625130
  53. Muss HB, D'Alessandro HA, Brachtel EF. Case 15-2010 - an 85-year-old woman with mammographically detected early breast cancer. N Engl J Med 2010; 362:1921-1928; May 20, 2010. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20484399
  54. 54.0 54.1 Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011 Feb 9; 305:569-575 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21304082 <Internet> http://jama.ama-assn.org/content/305/6/569.full?ijkey=ccab36bf5ba7ddb24a641431d347685c28101490&keytype2=tf_ipsecsha
    Carlson GW and Wood WC. Management of axillary lymph node metastasis in breast cancer: Making progress. JAMA 2011 Feb 9; 305:606. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21304087 <Internet> http://jama.ama-assn.org/content/305/6/606.full?ijkey=149b53cdd8c0a4d6875c3b88448240a1a2ed2187&keytype2=tf_ipsecsha
  55. 55.0 55.1 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011 Nov 12; 378:1707 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22019144
    Buchholz TA. Radiotherapy and survival in breast cancer. Lancet 2011 Nov 12; 378:1680 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22019143
  56. 56.0 56.1 Koppelmans V et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012 Feb 27 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22370315 <Internet> http://jco.ascopubs.org/content/early/2012/02/27/JCO.2011.37.0189
  57. 57.0 57.1 Kalager M et al Overdiagnosis of Invasive Breast Cancer Due to Mammography Screening: Results From the Norwegian Screening Program Annals of Internal Medicine April 3, 2012, 156(7):491-499 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22473436 <Internet> http://www.annals.org/content/156/7/491.abstract
    Elmore JG and Fletcher SW Overdiagnosis in Breast Cancer Screening: Time to Tackle an Underappreciated Harm Annals of Internal Medicine April 3, 2012, 156(7):536-537 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22473439 <Internet> http://www.annals.org/content/156/7/536.extract
  58. Curtis C et al The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature April 18, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22522925 <Internet> http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10983.html
  59. 59.0 59.1 Kesson EM et al. Effects of multidisciplinary team working on breast cancer survival: Retrospective, comparative, interventional cohort study of 13,722 women. BMJ 2012 Apr 26; 344:e2718. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22539013
  60. 60.0 60.1 Smith GL et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 2012 May 2; 307:1827. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22550197
  61. 61.0 61.1 ARUP Consult: Breast Cancer Biomarkers The Physician's Guide to Laboratory Test Selection & Interpretation https://www.arupconsult.com/content/breast-cancer
    ARUP Consult: Hereditary Breast and Ovarian Cancer https://arupconsult.com/ati/hereditary-breast-and-ovarian-cancer
  62. 62.0 62.1 Mehta RS et al Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. N Engl J Med 2012; 367:435-444August 2, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22853014 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa120162264) Haque R et al
  63. 63.0 63.1 63.2 Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades Cancer Epidemiology, Biomarkers & Prevention, Sept 18, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22989461 <Internet> http://cebp.aacrjournals.org/content/early/2012/09/17/1055-9965.EPI-12-0474.abstract#aff-1
  64. 64.0 64.1 The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature (2012) Sept 23, <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23000897 <Internet> http://www.nature.com/nature/journal/vaop/ncurrent/full/nature11412.html
  65. 65.0 65.1 Centers for Disease Control and Prevention Vital Signs: Racial Disparities in Breast Cancer Severity - United States, 2005-2009 MMWR. November 14, 2012 / 61(Early Release);1-6 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23151952 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/mm61e1114a1.htm
  66. 66.0 66.1 66.2 Johnson RH et al Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009. JAMA. 2013;309(8):800-805 http://jama.jamanetwork.com/article.aspx?articleid=1656255
  67. 67.0 67.1 67.2 Dawson SJ et al Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. N Engl J Med. March 13, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23484797 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1213261
  68. Tirona MT, Sehgal R, Ballester O Prevention of breast cancer (Part II): risk reduction strategies. Cancer Invest. 2010 Dec;28(10):1070-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20932221
  69. 69.0 69.1 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15894097
  70. 70.0 70.1 McCready D, Holloway C, Shelley W et al Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg. 2005 Jun;48(3):185-94. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16013621
  71. 71.0 71.1 Tolaney SM, Winer EP. Follow-up care of patients with breast cancer. Breast. 2007 Dec;16 Suppl 2:S45-50. Epub 2007 Aug 13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17697780
  72. 72.0 72.1 Beslija S, Bonneterre J, Burstein HJ et al Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009 Nov;20(11):1771-85. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19608616
  73. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008 Feb 10;26(5):786-90 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18258987
  74. Clarke M, Collins R, Darby S Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17;366(9503):2087-106. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16360786
  75. Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park). 2008 May;22(6):614-23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18561551
  76. Hermelink K, Untch M, Lux MP et al Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007 May 1;109(9):1905-13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17351951
  77. Hillner BE, Ingle JN, Chlebowski RT et al American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Nov 1;21(21):4042-57. Epub 2003 Sep 8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12963702
  78. 78.0 78.1 Webb ML et al A failure analysis of invasive breast cancer. Most deaths from disease occur in women not regularly screened. Cancer. September 9. 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24018987 <Internet> http://onlinelibrary.wiley.com/doi/10.1002/cncr.28199/abstract
  79. 79.0 79.1 Haviland JS et al The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. The Lancet Oncology, Early Online Publication, 19 September 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24055415 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70386-3/abstract
  80. 80.0 80.1 Schnipper LE et al American Society of Clinical Oncology 2013 Top Five List in Oncology. Journal of Clinical Oncology. October 29, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24170249 <Internet> http://jco.ascopubs.org/content/early/2013/10/29/JCO.2013.53.3943
  81. 81.0 81.1 Bender CM et al. Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer? Menopause 2013 Sep; 20:905 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23481123 <Internet> http://journals.lww.com/menopausejournal/pages/articleviewer.aspx?year=2013&issue=09000&article=00009&type=abstract
  82. 82.0 82.1 Moran MS et al. Society of Surgical Oncology - American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014 Feb 10 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24516019 <Internet> http://jco.ascopubs.org/content/early/2014/02/10/JCO.2013.53.3935
  83. 83.0 83.1 Ruddy KJ et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014 Feb 24 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24567428 <Internet> http://jco.ascopubs.org/content/early/2014/02/24/JCO.2013.52.8877
  84. 84.0 84.1 84.2 84.3 Lyman GH et al Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. March 24, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24663048 <Internet> http://jco.ascopubs.org/content/early/2014/03/18/JCO.2013.54.1177.full.pdf+html
  85. 85.0 85.1 Braithwaite D, Satariano WA, Sternfeld B et al Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010 Oct 6;102(19):1468-77 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20861456
  86. 86.0 86.1 Clough-Gorr KM, Stuck AE, Thwin SS, Silliman RA. Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol. 2010 Jan 20;28(3):380-6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20008637
  87. Klepin H, Mohile S, Hurria A. Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw. 2009 Feb;7(2):226-36 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19200420
  88. 88.0 88.1 Burstein HJ et al Adjuvant Endocrine Therapy for Women With Hormone Receptor- Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. May 27, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24868023 <Internet> http://jco.ascopubs.org/content/early/2014/05/20/JCO.2013.54.2258.abstract
  89. 89.0 89.1 89.2 Pagani O et al Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med. June 1, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24881463 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1404037
  90. 90.0 90.1 90.2 Medscape: Mulcahy N. June 17, 2014 Major Trial: No to Paclitaxel Alone in Early Breast Cancer. http://www.medscape.com/viewarticle/826900?nlid=59587_2202
  91. 91.0 91.1 Yu M et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014 Jul 11; 345:216 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25013076 <Internet> http://www.sciencemag.org/content/345/6193/216
  92. 92.0 92.1 92.2 92.3 Partridge AH et al Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. Sept. 2, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25185096 <Internet> http://jco.ascopubs.org/content/early/2014/09/02/JCO.2014.56.7479.full.pdf+html
  93. 93.0 93.1 Palta M et al The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: Changes in practice patterns after publication of Cancer and Leukemia Group B 9343. Cancer. Dec 8, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25488523 <Internet> http://onlinelibrary.wiley.com/doi/10.1002/cncr.28937/abstract
  94. Moy B et al Case 1-2015 - A 66-Year-Old Woman with Metastatic Breast Cancer after Endocrine Therapy. N Engl J Med 2015; 372:162-170. January 8, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25564900 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcpc1408601
  95. 95.0 95.1 Moore HC, Unger JM, Phillips KA, et al Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-932 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25738668 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1413204
  96. 96.0 96.1 Metcalfe K et al Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. Published online April 23, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26181175 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2276101
    Disis ML Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer. JAMA Oncol. Published online April 23, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26181176 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2276099
  97. 97.0 97.1 Easton DF et al Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. N Engl J Med. May 27, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26014596 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMsr1501341
    Phimister EG Curating the Way to Better Determinants of Genetic Risk N Engl J Med. May 27, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26014597 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1506276
  98. 98.0 98.1 98.2 Chagpar AB et al A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. May 30, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26028131 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1504473
  99. 99.0 99.1 99.2 Liu FF et al. Identification of a low-risk luminal A breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol 2015 May 11; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/25964246
    Bellon JR. Personalized radiation oncology for breast cancer: The new frontier. J Clin Oncol 2015 May 11; PMID: https://www.ncbi.nlm.nih.gov/pubmed/25964251
  100. 100.0 100.1 Brinton LA et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol 2015 Jun 20; 33:2041. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25964249
  101. 101.0 101.1 101.2 101.3 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. Published Online: 23 July 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26211827 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2961074-1/abstract
    Mayer EL, Burstein HJ Postmenopausal breast cancer: a best endocrine strategy? Lancet. Published Online: 23 July 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26211823 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2961206-5/abstract
  102. 102.0 102.1 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. Published Online: 23 July 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26211824 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960908-4/abstract
    Brufsky A, Mathew A Bisphosphonates, bone, and breast cancer recurrence. Lancet. Published Online: 23 July 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26211825 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2961163-1/abstract
  103. 103.0 103.1 Desmond A et al Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol. Published online August 13, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26270727 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2425836
    Swisher EM Usefulness of Multigene Testing. Catching the Train That's Left the Station. JAMA Oncol. Published online August 13, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26270409 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2425834
  104. 104.0 104.1 Saadatmand S et al Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 2015;351:h4901 http://www.bmj.com/content/351/bmj.h4901
    Vaz-Luis I, Burstein HJ. With better adjuvant therapy, does breast cancer stage still matter? BMJ 2015;351:h5273 http://www.bmj.com/content/351/bmj.h5273
  105. Amir E, Miller N, Geddie W et al Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012 Feb 20;30(6):587-92 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22124102
  106. Baselga J, Campone M, Piccart M et al Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22149876
  107. Hughes KS, Schnaper LA, Bellon JR et al Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long- term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;31(19):2382-7 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23690420
  108. Khatcheressian JL, Hurley P, Bantug E et al Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1;31(7):961-5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23129741
  109. Kaufmann M, Hortobagyi GN, Goldhirsch A et al Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006 Apr 20;24(12):1940-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16622270
  110. 110.0 110.1 Gluck S Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action. Clin Breast Cancer. 2014 Apr;14(2):75-84. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24355138
  111. 111.0 111.1 Malone KE, Begg CB, Haile RW et al Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010 May 10;28(14):2404-10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20368571
  112. Hayes DF Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med. 2007 Jun 14;356(24):2505-13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17568031
  113. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21067385
  114. Harris LN et al Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. Feb 8, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26858339 <Internet> http://jco.ascopubs.org/content/early/2016/02/05/JCO.2015.65.2289.full.pdf+html
  115. 115.0 115.1 Marinac CR et al Prolonged Nightly Fasting and Breast Cancer Prognosis. JAMA Oncol. Published online March 31, 2016. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27032109 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2506710
  116. 116.0 116.1 Goss PE, Ingle JN, Pritchard KI et al Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. June 5, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27264120 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1604700
    Chlebowski RT, Budoff MJ Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. N Engl J Med. June 5, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27263869 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1606031
  117. 117.0 117.1 Cortadellas T, Gascon A, Cordoba O et al Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer. Int J Surg. 2013;11(7):554-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23721662 Free Article
  118. Kiderlen M, Bastiaannet E, Walsh PM et al Surgical treatment of early stage breast cancer in elderly: an international comparison. Breast Cancer Res Treat. 2012 Apr;132(2):675-82. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22119939 Free PMC Article
  119. 119.0 119.1 Accordino MK et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol 2016 Aug 20; 34:2820. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27161970
    Smith KL, Smith TJ. Reining in the excessive use of medical tests: What are the next steps? J Clin Oncol 2016 Aug 20; 34:2807 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27354475
  120. American Society of Clincal Oncology. September 19, 2016. Breast Cancer. Postmastectomy Radiotherapy. http://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/9841
  121. 121.0 121.1 Orciari Herman A, Sofair A, Chavey WE Adjuvant Endocrine Therapy Linked to Reduced Risk for Contralateral Breast Cancer in Community Setting. Physician's First Watch, Oct 7, 2016 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    Gierach GL, Curtis RE, Pfeiffer RM et al Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncology. Oct 6, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27711920 <Internet> http://jamanetwork.com/journals/jamaoncology/article-abstract/2565154
    Abderrahman B, Jordan VC Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer. JAMA Oncology. Oct 6, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27711910 <Internet> http://jamanetwork.com/journals/jamaoncology/article-abstract/2565152
  122. 122.0 122.1 Lyman GH, Somerfield MR, Bosserman LD et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2016 Dec 12; PMID: https://www.ncbi.nlm.nih.gov/pubmed/27937089
    Caudle AS, Yang WT, Krishnamurthy S et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol 2016 Apr 1; 34:1072 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26811528 Free PMC Article
  123. 123.0 123.1 Priedigkeit N, Hartmaier RJ, Chen Y et al Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncol. Published online December 7, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27926948 <Internet> http://jamanetwork.com/journals/jamaoncology/article-abstract/2588642
  124. 124.0 124.1 Kurian AW et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA 2017 Feb 7; 317:531 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28170472 <Internet> http://jamanetwork.com/journals/jama/article-abstract/2600457
  125. 125.0 125.1 Ri G, Ohno S, Yamamoto T et al Serum levels of CA15-3, KL-6 and BCA225 are positively correlated with each other in the general population. Anticancer Res. 2009 Oct;29(10):4239-42. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19846980 Free Article
  126. 126.0 126.1 Lannin DR, Wang S Are Small Breast Cancers Good because They Are Small or Small because They Are Good? N Engl J Med 2017; 376:2286-91. June 8, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28591529 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMsr1613680
  127. Romanoff A et al. Association of previous clinical breast examination with reduced delays and earlier-stage breast cancer diagnosis among women in Peru. JAMA Oncol 2017 May 25; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28542677 <Internet> http://jamanetwork.com/journals/jamaoncology/article-abstract/2628761
  128. 128.0 128.1 Masuda N, Lee SJ, Ohtani S et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017 Jun 1; 376:2147. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28564564 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1612645
  129. 129.0 129.1 Harrison P Simple Two-Drug Combo May Inhibit Metastases in Breast Cancer. Medscape - Aug 15, 2017. http://www.medscape.com/viewarticle/884293
    Shaashua L, Shabat-Simon M, Haldar R et al Perioperative COX-2 and beta-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. Clin Cancer Res. 2017 Aug 15;23(16):4651-4661. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28490464 .
  130. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome. Obstetrics & Gynecology. 130(3):657-659, SEP 2017 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28832475 https://insights.ovid.com/crossref?an=00006250-201709000-00035
  131. 131.0 131.1 131.2 Giuliano AE, Ballman KV, McCall L et al Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-926 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28898379 <Internet> http://jamanetwork.com/journals/jama/article-abstract/2653737
  132. 132.0 132.1 Donnez J, Dolmans MM Fertility Preservation in Women. N Engl J Med 2017; 377:1657-1665. October 26, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29069558 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMra1614676
  133. 133.0 133.1 Colleoni M, Luo W, Karlsson P et al Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Nov 17, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29158011 <Internet> http://thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30715-5/fulltext
    Chlebowski RT, Pan K. Complexity of intermittent letrozole adjuvant therapy. The Lancet Oncology. Nov 17, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29158010 <Internet> http://thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30854-9/fulltext
  134. 134.0 134.1 Davenport L Only 2 Years of Extended Anastrozole Needed in Breast Cancer Medscape - Dec 08, 2017. https://www.medscape.com/viewarticle/889788
  135. 135.0 135.1 135.2 FDA News Release. Dec 22, 2017 FDA clears stereotactic radiotherapy system for use in treating breast cancer. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590313.htm
  136. 136.0 136.1 Smith BD, Bellon JR, Blitzblau R, et al Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence- based guideline. Pract Radiat Oncol. 2018 Mar 12 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29545124 <Internet> http://www.practicalradonc.org/article/S1879-8500(18)30051-1/pdf
  137. 137.0 137.1 137.2 Sparano JA, Gray RJ, Makower DF et al Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. June 3, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29860917 https://www.nejm.org/doi/full/10.1056/NEJMoa1804710
    ASCO News Release. June 3, 2018 Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test. https://www.asco.org/about-asco/press-center/news-releases/most-women-early-stage-breast-cancer-can-forgo-chemotherapy
  138. 138.0 138.1 MedPage Today Staff NICE Rejects Adjuvant Perjeta in HER2 Breast Cancer. In contrast with FDA, Britain's cost watchdog says drug may not offer 'meaningful' benefit. MedPage Today. June 14, 2018 https://www.medpagetoday.com/hematologyoncology/breastcancer/73509
  139. 139.0 139.1 139.2 139.3 Luen SJ, Asher R, Lee CK et al Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast CancerA Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. JAMA Oncol. Published online June 14, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29902286 https://jamanetwork.com/journals/jamaoncology/fullarticle/2684637
    Stearns V, Park BH PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers. PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions. JAMA Oncol. Published online June 14, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29902310 https://jamanetwork.com/journals/jamaoncology/fullarticle/2684628
  140. 140.0 140.1 Fuerst ML with expert critique by Sumrall AL Advanced TNBC: 'Durable Activity' for Niraparib + Pembrolizumab. Also benefit for platinum-resistant/refractory ovarian cancer. MedPage Today. ASCO Reading Room 06.21.2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/73611
  141. 141.0 141.1 Zacharakis N, Chinnasamy H, Black M et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 2018 Jun; 24:724. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29867227 https://www.nature.com/articles/s41591-018-0040-8
    Radvanyi LG. Targeting the cancer mutanome of breast cancer. Nat Med 2018 Jun; 24:703 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29867234 https://www.nature.com/articles/s41591-018-0065-z
  142. 142.0 142.1 142.2 Tang V, Zhao S, Boscardin J et al Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents. JAMA Surg. Published online August 29, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30167636 https://jamanetwork.com/journals/jamasurgery/fullarticle/2697211
  143. 143.0 143.1 Galimberti V, Cole BF, Viale Get al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018 Sep 5; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30196031
  144. Tevaarwerk AJ, Wisinski KB, O'Regan RM. Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. J Oncol Pract. 2016 Nov;12(11):1148-1156. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27858538
  145. 145.0 145.1 145.2 Kuznar W with expert critique by Gnanajothy R No Cognitive Decline in Most Older Women With Breast Cancer. Problem found mostly in those who are ApoE ?4-positive. MedPage Today. ASCO Reading Room 01.15.2019 https://www.medpagetoday.com/reading-room/asco/breast-cancer/77427
  146. 146.0 146.1 146.2 Grassmann F, He W, Eriksson M et al Interval breast cancer is associated with other types of tumors. Nature Communications volume 10, Article number: 4648 (2019) PMID: https://www.ncbi.nlm.nih.gov/pubmed/31641120 https://www.nature.com/articles/s41467-019-12652-1
    Niraula S, Biswanger N, Hu P et al Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers. JAMA Netw Open. 2020;3(9):e2018179. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32975573 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770959
  147. 147.0 147.1 Whelan TJ, Julian JA, Berrang TS et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): A randomised controlled trial. Lancet 2019 Dec 14; 394:2165-2172. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31813635
  148. 148.0 148.1 Ma SJ, Oladeru OT, Singh AK et al. Association of survival with chemoendocrine therapy in women with small, hormone receptor-positive, ERBB2-positive, node-negative breast cancer. JAMA Netw Open 2020 Apr 1; 3:e202507 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32271387 Free PMC Article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764231
  149. 149.0 149.1 Lowry F Eye-Opening': Cognitive Decline With Endocrine Tx for Breast Ca. Medscape - Apr 22, 2020 https://www.medscape.com/viewarticle/929169
    Wagner LI, Gray RJ, Sparano JA et al Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. April 9, 2020 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32271671 https://ascopubs.org/doi/10.1200/JCO.19.01866
  150. 150.0 150.1 Branigan GL, Soto M, Neumayer L, Rodgers K, Brinton RD. Association between hormone-modulating breast cancer therapies and incidence of neurodegenerative outcomes for women with breast cancer. JAMA Netw Open 2020 Mar 24; 3:e201541. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32207833 Free PMC Article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2763234
  151. 151.0 151.1 NIH News Relerase. Dec 9, 2020 Some postmenopausal women with common breast cancer may forgo chemotherapy. https://www.nih.gov/news-events/news-releases/some-postmenopausal-women-common-breast-cancer-may-forgo-chemotherapy
  152. Burstein HJ Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med 2020; 383:2557-2570. Dec 24 Review PMID: https://www.ncbi.nlm.nih.gov/pubmed/33369357 https://www.nejm.org/doi/full/10.1056/NEJMra1307118
  153. 153.0 153.1 Loomans-Kropp HA, Pinsky P, Umar A. Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. JAMA Netw Open. 2021;4(1):e2032072. Jan 15 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33449095 PMCID: PMC7811183 Free PMC article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775219
  154. 154.0 154.1 154.2 Hu C, Hart SN, Gnanaolivu R et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med 2021 Feb 4; 384:440 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33471974 https://www.nejm.org/doi/10.1056/NEJMoa2005936
    Dorling L, Carvalho S, Allen J et al. Breast cancer risk genes - Association analysis in more than 113,000 women. N Engl J Med 2021 Feb 4; 384:428 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33471991 https://www.nejm.org/doi/10.1056/NEJMoa1913948
    Narod SA. Which genes for hereditary breast cancer? N Engl J Med 2021 Feb 4; 384:471 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33471975 https://www.nejm.org/doi/10.1056/NEJMe2035083
  155. 155.0 155.1 Friedl TWP, Fehm T, Muller V et al Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment. A Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online June 24, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34165508 https://jamanetwork.com/journals/jamaoncology/fullarticle/2781088
    Desnoyers A, Amir E, Tannock IF Adjuvant Zoledronate Therapy for Women With Breast Cancer - Effective Treatment or Fool's Gold? JAMA Oncol. Published online June 24, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34165515 https://jamanetwork.com/journals/jamaoncology/fullarticle/2781092
  156. 156.0 156.1 de Boniface J, Szulkin R, Johansson ALV Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status. A Swedish National 6-Year Follow-up of 48,986 Women. JAMA Surg. 2021;156(7):628-637 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33950173 PMCID: PMC8100916 Free PMC article https://jamanetwork.com/journals/jamasurgery/fullarticle/2779531
  157. 157.0 157.1 Tamirisa N, Lin H, Shen Y et al. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer - A National Cancer Database analysis. Cancer 2021 Jul 1; 127:2196. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33735487 PMCID: PMC8195825 (available on 2022-07-01) https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33489
  158. 158.0 158.1 Van Dyk K, Ganz PA. Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer. JAMA. Published online October 15, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34652424 https://jamanetwork.com/journals/jama/fullarticle/2785382
  159. 159.0 159.1 Kalinsky K, Barlow WE, Gralow JR et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 2021 Dec 16; 385:2336 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34914339 https://www.nejm.org/doi/10.1056/NEJMoa2108873
  160. 160.0 160.1 160.2 160.3 160.4 Breast Cancer Association Consortium Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. Published online January 27, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35084436 https://jamanetwork.com/journals/jamaoncology/fullarticle/2788577
  161. Waks AG, Winer EP Breast Cancer Treatment. A Review. JAMA. 2019;321(3):288-300. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30667505 https://jamanetwork.com/journals/jama/fullarticle/2721183
  162. 162.0 162.1 Brooks M 'Unexpected': Breast Cancer Spreads Most During Sleep. Medscape. June 28, 2022 https://www.medscape.com/viewarticle/976293
    Diamantopoulou1 Z, Castro-Giner F, Schwab FD et al The metastatic spread of breast cancer accelerates during sleep. Nature. 2022. June 22 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35732738 https://www.nature.com/articles/s41586-022-04875-y.epdf
  163. Breast Cancer (PDQ): Treatment http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional
    Breast Cancer and Pregnancy (PDQ) http://www.cancer.gov/cancertopics/pdq/treatment/breast-cancer-and-pregnancy/HealthProfessional
    Male Breast Cancer (PDQ): Treatment http://www.cancer.gov/cancertopics/pdq/treatment/malebreast/HealthProfessional
    Cellular Classification of Breast Cancer http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3

Patient information

breast cancer patient information

Database